Exceeded fourth quarter 2024 financial guidance for revenue with 9 percent growth driven by U.S. Markets Financial Services and Insurance ...

Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and ...

Global Inc. (SPIR) reported strong revenue growth for the fourth quarter of 2024, but its stock experienced significant volatility. Despite a 13% increase in quarterly revenue, the stock price fell ...

The Daughters of Isabella, Haubstadt Circle 151, convened at the Knights of Columbus Hall in Haubstadt Jan. 20 for a regular meeting. The meeting was opened by Regent ...

Oral hearings heard the USPTO side with MSD (Merck) over a term extension for a reissued patent, in a case set to have huge implications for pharma market exclusivity, reports Marisa Woutersen.